The Use of Laboratory Determinations in the Control of Streptokinase Therapy

The purpose of this pilot study on a small cohort of patients (n = 13) with acute myocardial infarction receiving systemic streptokinase (STK) thrombolytic therapy was to measure the decrease in plasma viscosity concomitant with fibrinogen depletion. The treatment group was compared with a similar control group not given thrombolytic therapy. Serial relevant blood studies were undertaken in both groups for a period of 6 d. In the treatment group, a maximum reduction in plasma viscosity of 17 ± 9% (mean ± S.D.) was achieved during the first 24 h. Plasma viscosity remained below baseline for the 6‐d duration of the study. Conversely, in the control group, the plasma viscosity rose to a maximum of 19 ± 14% (mean ± S.D.) over the period of study, parallelling the rise in plasma fibrinogen as an acute‐phase reactant. Correlation studies between viscosity and plasma fibrinogen were strongly positive with mean values of r of 0.74 and 0.66 in the STK‐treated group and controls, respectively. We conclude that the benefit of systemic STK treatment may in part be due to reduced myocardial workload and oxygen consumption at a critical time, and improved microvascular circulation, consequent on reduced plasma viscosity.

show abstract

The Use of Laboratory Determinations in the Control of Streptokinase Therapy

Cited by 4 publications

References 0 publications

Clinical Use of Streptokinase

Clinical Use of Streptokinase

Experimental disseminated intravascular coagulation effect of heparin and e-aminocaproic acid on test of hemostatic function

Streptokinase and reduced plasma viscosity: A second benefit

Contact Info

Product

Resources

About